A licensed provider will assess your health history and determine whether semaglutide or tirzepatide is appropriate for you
Compounded tirzepatide Tirzepatide is a dual GIP/GLP-1 receptor agonist, originally marketed as Mounjaro and Zepbound by Eli Lilly
A study of 30 patients with type 2 diabetes treated for 8 weeks showed measurable reductions in CD62p (a marker of platelet activation) and PAC-1 (a marker of glycoprotein IIb/IIIa complex activation, the final common pathway of platelet aggregation)
Prepare the Site Choose your spot (abdomen, thigh, or arm)
MRM transitions and collision energies are reported in Supplemental Material 1
January 2026 is aligning with commonly observed early-year interest in oral GLP-1 peptide options, as consumers compare different administration formats during seasonal "new year, new you" wellness behavior